Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056

Hye Ryun Kim; Joung Soon Jang; Jong Mu Sun; Myung Ju Ahn; Dong Wan Kim; Inkyung Jung; Ki Hyeong Lee; Joo Hang Kim; Dae Ho Lee; Sang We Kim; Byoung Chul Cho

doi:10.18632/oncotarget.20268

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056

Hye Ryun Kim, Joung Soon Jang, Jong Mu Sun, Myung Ju Ahn, Dong Wan Kim, Inkyung Jung, Ki Hyeong Lee, Joo Hang Kim, Dae Ho Lee, Sang We Kim, Byoung Chul Cho

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Present: The current funding information is incomplete. Correct: The complete funding information is given below.

Original language	English
Pages (from-to)	55766
Number of pages	1
Journal	Oncotarget
Volume	8
Issue number	33
DOIs	https://doi.org/10.18632/oncotarget.20268
Publication status	Published - 2017

Bibliographical note

Funding Information:
This study was supported partly by Astra Zeneca Korea Ltd. This study was supported in part by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1440, B. C. Cho), a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1948 to H.R. Kim) and a faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0134, B.C. Cho.)..

Publisher Copyright:
© Kim et al.

All Science Journal Classification (ASJC) codes

Oncology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.18632/oncotarget.20268

Fingerprint Dive into the research topics of 'Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056'. Together they form a unique fingerprint.

Cite this

Kim, H. R., Jang, J. S., Sun, J. M., Ahn, M. J., Kim, D. W., Jung, I., Lee, K. H., Kim, J. H., Lee, D. H., Kim, S. W., & Cho, B. C. (2017). Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056. Oncotarget, 8(33), 55766. https://doi.org/10.18632/oncotarget.20268

Kim, Hye Ryun ; Jang, Joung Soon ; Sun, Jong Mu ; Ahn, Myung Ju ; Kim, Dong Wan ; Jung, Inkyung ; Lee, Ki Hyeong ; Kim, Joo Hang ; Lee, Dae Ho ; Kim, Sang We ; Cho, Byoung Chul. / Correction : A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056. In: Oncotarget. 2017 ; Vol. 8, No. 33. pp. 55766.

@article{9188174309ad49b1a302f46538984152,

title = "Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056",

abstract = "Present: The current funding information is incomplete. Correct: The complete funding information is given below.",

author = "Kim, {Hye Ryun} and Jang, {Joung Soon} and Sun, {Jong Mu} and Ahn, {Myung Ju} and Kim, {Dong Wan} and Inkyung Jung and Lee, {Ki Hyeong} and Kim, {Joo Hang} and Lee, {Dae Ho} and Kim, {Sang We} and Cho, {Byoung Chul}",

note = "Funding Information: This study was supported partly by Astra Zeneca Korea Ltd. This study was supported in part by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1440, B. C. Cho), a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1948 to H.R. Kim) and a faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0134, B.C. Cho.).. Publisher Copyright: {\textcopyright} Kim et al.",

year = "2017",

doi = "10.18632/oncotarget.20268",

language = "English",

volume = "8",

pages = "55766",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "33",

}

Kim, HR, Jang, JS, Sun, JM, Ahn, MJ, Kim, DW, Jung, I, Lee, KH, Kim, JH, Lee, DH, Kim, SW & Cho, BC 2017, 'Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056', Oncotarget, vol. 8, no. 33, pp. 55766. https://doi.org/10.18632/oncotarget.20268

Correction : A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056. / Kim, Hye Ryun; Jang, Joung Soon; Sun, Jong Mu; Ahn, Myung Ju; Kim, Dong Wan; Jung, Inkyung; Lee, Ki Hyeong; Kim, Joo Hang; Lee, Dae Ho; Kim, Sang We; Cho, Byoung Chul.

In: Oncotarget, Vol. 8, No. 33, 2017, p. 55766.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction

T2 - A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056

AU - Kim, Hye Ryun

AU - Jang, Joung Soon

AU - Sun, Jong Mu

AU - Ahn, Myung Ju

AU - Kim, Dong Wan

AU - Jung, Inkyung

AU - Lee, Ki Hyeong

AU - Kim, Joo Hang

AU - Lee, Dae Ho

AU - Kim, Sang We

AU - Cho, Byoung Chul

N1 - Funding Information: This study was supported partly by Astra Zeneca Korea Ltd. This study was supported in part by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1440, B. C. Cho), a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1948 to H.R. Kim) and a faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0134, B.C. Cho.).. Publisher Copyright: © Kim et al.

PY - 2017

Y1 - 2017

N2 - Present: The current funding information is incomplete. Correct: The complete funding information is given below.

AB - Present: The current funding information is incomplete. Correct: The complete funding information is given below.

UR - http://www.scopus.com/inward/record.url?scp=85029092649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029092649&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20268

DO - 10.18632/oncotarget.20268

M3 - Comment/debate

AN - SCOPUS:85029092649

VL - 8

SP - 55766

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 33

ER -

Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I et al. Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056. Oncotarget. 2017;8(33):55766. https://doi.org/10.18632/oncotarget.20268

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this